Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243828 | 0.80 | HTT (0.48) | MAPTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL2557500 | 0.79 | ALDH1A1 (0.60) | MAPTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL22616889 | 0.78 | ALDH1A1 (0.43) | MAPTALDH1A1CYP3A4ALOX15HTT | |
| SCHEMBL19664859 | 0.78 | ALDH1A1 (0.43) | MAPTALDH1A1CYP3A4ALOX15HTT | |
| SCHEMBL19664861 | 0.78 | ALDH1A1 (0.43) | MAPTALDH1A1CYP3A4ALOX15HTT | |
| SCHEMBL28068351 | 0.78 | ALDH1A1 (0.62) | MAPTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL27882095 | 0.76 | ALDH1A1 (0.60) | MAPTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL28428327 | 0.76 | ALDH1A1 (0.60) | MAPTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL3387313 | 0.76 | ALDH1A1 (0.55) | MAPTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL2385986 | 0.75 | CYP1A2 (0.64) | MAPTALDH1A1CYP3A4ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323990-B1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | DYNAMIT NOBEL AG (DE) | 2014-06-18 | — | — | EP | claimed |
| US-8558005-B2 | Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF-UND SYSTEMTECHNIK (DE) | 2013-10-15 | — | — | US | claimed |
| JP-2012500183-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110178308-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | claimed |
| EP-2323990-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 2011-05-25 | — | — | EP | claimed |
| WO-2010021409-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF - UND SYSTEMTECHNIK (DE) | 2010-02-25 | — | — | WO | claimed |
| EP-2323990-B1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | DYNAMIT NOBEL AG (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8558005-B2 | Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF-UND SYSTEMTECHNIK (DE) | 2013-10-15 | — | — | US | disclosed |
| US-20110178308-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2323990-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010143007-A1 | METHOD FOR THE PRODUCTION OF 2-HALOGENO-4-NITROIMIDAZOLE | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF-UND SYSTEMTECHNIK (DE) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010021409-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF - UND SYSTEMTECHNIK (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178308-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | IL4I1, NUDT1, NISCH | MAPT 3868/4885ALDH1A1 704/4885CYP3A4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.